

Stephen Senn

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/6012626/publications.pdf>

Version: 2024-02-01

218
papers

11,141
citations

81434

41
h-index

45040

94
g-index

299
all docs

299
docs citations

299
times ranked

13150
citing authors

#	ARTICLE	IF	CITATIONS
1	Empirical studies of balance do not justify a requirement for 1,000 patients per trial. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 184-188.	2.4	1
2	Ten simple rules for good research practice. <i>PLoS Computational Biology</i> , 2022, 18, e1010139.	1.5	12
3	The design and analysis of vaccine trials for COVID-19 for the purpose of estimating efficacy. <i>Pharmaceutical Statistics</i> , 2022, 21, 790-807.	0.7	4
4	Viewpoint : Do not resurrect the two-stage procedure. <i>Pharmaceutical Statistics</i> , 2022, 21, 808-814.	0.7	0
5	Implementing Historical Controls in Oncology Trials. <i>Oncologist</i> , 2021, 26, e859-e862.	1.9	12
6	Stephen Senn's contribution to the Discussion of "Testing by betting: A strategy for statistical and scientific communication" by Glenn Shafer. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2021, 184, 459-460.	0.6	0
7	The statistical properties of RCTs and a proposal for shrinkage. <i>Statistics in Medicine</i> , 2021, 40, 6107-6117.	0.8	18
8	The outstanding scientist, R.A. Fisher: his views on eugenics and race. <i>Heredity</i> , 2021, 126, 565-576.	1.2	6
9	Giving and taking: ethical treatment assignment in controlled trials. <i>Journal of the Royal Society of Medicine</i> , 2021, 114, 525-530.	1.1	1
10	Clustered allocation as a way of understanding historical controls: Components of variation and regulatory considerations. <i>Statistical Methods in Medical Research</i> , 2020, 29, 1960-1971.	0.7	11
11	Demonstrating Heterogeneity of Treatment Effects Among Patients: An Overlooked but Important Step Toward Precision Medicine. <i>Clinical Pharmacology and Therapeutics</i> , 2019, 106, 204-210.	2.3	24
12	Treatment Effects in Multicenter Randomized Clinical Trials. <i>JAMA - Journal of the American Medical Association</i> , 2019, 321, 1211.	3.8	8
13	John Ashworth Nelder. 8 October 1924–7 August 2010. <i>Biographical Memoirs of Fellows of the Royal Society</i> , 2019, 67, 307-326.	0.1	0
14	Random main effects of treatment: A case study with a network meta-analysis. <i>Biometrical Journal</i> , 2019, 61, 379-390.	0.6	8
15	Sample size considerations for n -of-1 trials. <i>Statistical Methods in Medical Research</i> , 2019, 28, 372-383.	0.7	43
16	Childhood asthma exacerbations and ADRB2 polymorphism: Caution is needed. <i>Journal of Allergy and Clinical Immunology</i> , 2018, 141, 1954-1955.	1.5	3
17	Statistical pitfalls of personalized medicine. <i>Nature</i> , 2018, 563, 619-621.	13.7	129
18	Lessons learned from IDEAL – 33 recommendations from the IDEAL-net about design and analysis of small population clinical trials. <i>Orphanet Journal of Rare Diseases</i> , 2018, 13, 77.	1.2	22

#	ARTICLE	IF	CITATIONS
19	Statistical Analysis Plans for Clinical Trialsâ€”Reply. JAMA - Journal of the American Medical Association, 2018, 319, 1938.	3.8	0
20	Does evidence support the high expectations placed in precision medicine? A bibliographic review. F1000Research, 2018, 7, 30.	0.8	17
21	Does evidence support the high expectations placed in precision medicine? A bibliographic review. F1000Research, 2018, 7, 30.	0.8	14
22	Statistical issues in first-in-human studies on BIA 102474: Neglected comparison of protocol against practice. Pharmaceutical Statistics, 2017, 16, 100-106.	0.7	11
23	Contribution to the discussion of â€”a critical evaluation of the current <i>p</i> -value controversyâ€”™. Biometrical Journal, 2017, 59, 892-894.	0.6	3
24	Defining drug response for stratified medicine. Drug Discovery Today, 2017, 22, 173-179.	3.2	24
25	Guidelines for the Content of Statistical Analysis Plans in Clinical Trials. JAMA - Journal of the American Medical Association, 2017, 318, 2337.	3.8	290
26	Cushny and Peebles, optical isomers and the birth of modern statistics. Journal of the Royal Society of Medicine, 2017, 110, 501-502.	1.1	0
27	Mastering variation: variance components and personalised medicine. Statistics in Medicine, 2016, 35, 966-977.	0.8	143
28	A Chronicle of Permutation Statistical Methods: 1920â€”2000, and Beyond, by K J Berry, J E Johnston, and P J W Mielke. Bulletin of the British Society for the History of Mathematics, 2016, 31, 155-156.	0.1	1
29	Statistical tests, P values, confidence intervals, and power: a guide to misinterpretations. European Journal of Epidemiology, 2016, 31, 337-350.	2.5	1,761
30	Reporting of cross-over clinical trials of analgesic treatments for chronic pain: Analgesic, Anesthetic, and Addiction Clinical Trial Translations, Innovations, Opportunities, and Networks systematic review and recommendations. Pain, 2016, 157, 2544-2551.	2.0	16
31	Understanding Variation in Sets of N-of-1 Trials. PLoS ONE, 2016, 11, e0167167.	1.1	59
32	Individual response to exercise training - a statistical perspective. Journal of Applied Physiology, 2015, 118, 1450-1459.	1.2	204
33	Progression-seeking bias and rational optimism in research and development. Nature Reviews Drug Discovery, 2015, 14, 219-221.	21.5	12
34	Various varying variances: The challenge of nuisance parameters to the practising biostatistician. Statistical Methods in Medical Research, 2015, 24, 403-419.	0.7	22
35	R&D productivity rides again?. Pharmaceutical Statistics, 2015, 14, 1-3.	0.7	20
36	Drug development: EU paediatric legislation, the European Medicines Agency and its Paediatric Committeeâ€”adolescentsâ€”™ melanoma as a paradigm. Pharmaceutical Statistics, 2014, 13, 211-213.	0.7	18

#	ARTICLE	IF	CITATIONS
37	A note regarding "random effects". <i>Statistics in Medicine</i> , 2014, 33, 2876-2877.	0.8	18
38	Interpreting patient treatment response in analgesic clinical trials: Implications for genotyping, phenotyping, and personalized pain treatment. <i>Pain</i> , 2014, 155, 457-460.	2.0	33
39	A note regarding Lee's checks for minimum numbers of subjects where relative risks have been calculated. <i>Statistics in Medicine</i> , 2014, 33, 4135-4138.	0.8	0
40	Research designs for proof-of-concept chronic pain clinical trials: IMMPACT recommendations. <i>Pain</i> , 2014, 155, 1683-1695.	2.0	99
41	A note regarding meta-analysis of sequential trials with stopping for efficacy. <i>Pharmaceutical Statistics</i> , 2014, 13, 371-375.	0.7	7
42	Gastrointestinal Adverse Effects of Short-Term Aspirin Use: A Meta-Analysis of Published Randomized Controlled Trials. <i>Drugs in R and D</i> , 2013, 13, 9-16.	1.1	28
43	Comment on Gelman and Shalizi. <i>British Journal of Mathematical and Statistical Psychology</i> , 2013, 66, 65-67.	1.0	22
44	Issues in performing a network meta-analysis. <i>Statistical Methods in Medical Research</i> , 2013, 22, 169-189.	0.7	62
45	A Brief Note Regarding Randomization. <i>Perspectives in Biology and Medicine</i> , 2013, 56, 452-453.	0.3	2
46	Some issues in predicting patient recruitment in multi-centre clinical trials. <i>Statistics in Medicine</i> , 2013, 32, 5458-5468.	0.8	21
47	Invalid inversion. <i>Significance</i> , 2013, 10, 40-42.	0.3	6
48	Seven myths of randomisation in clinical trials. <i>Statistics in Medicine</i> , 2013, 32, 1439-1450.	0.8	177
49	Being Efficient About Efficacy Estimation. <i>Statistics in Biopharmaceutical Research</i> , 2013, 5, 204-210.	0.6	10
50	Bad karma. <i>Medical Writing</i> , 2013, 22, 252-255.	0.0	1
51	Authors are also reviewers: problems in assigning cause for missing negative studies. <i>F1000Research</i> , 2013, 2, 17.	0.8	5
52	What does randomisation achieve?. <i>Evidence-Based Medicine</i> , 2012, 17, 1-2.	0.6	11
53	Tea for Three: Of Infusions and Inferences and Milk in First. <i>Significance</i> , 2012, 9, 30-33.	0.3	26
54	The ghosts of departed quantities: approaches to dealing with observations below the limit of quantitation. <i>Statistics in Medicine</i> , 2012, 31, 4280-4295.	0.8	30

#	ARTICLE	IF	CITATIONS
55	Misunderstanding publication bias: editors are not blameless after all. F1000Research, 2012, 1, 59.	0.8	12
56	Echocardiographic Evidence for Valvular Toxicity of Benfluorex: A Double-Blind Randomised Trial in Patients with Type 2 Diabetes Mellitus. PLoS ONE, 2012, 7, e38273.	1.1	26
57	P-Values. , 2012, , 940-948.		0
58	Crossover Design. , 2012, , 380-385.		0
59	U is for Unease: Reasons for Mistrusting Overlap Measures for Reporting Clinical Trials. Statistics in Biopharmaceutical Research, 2011, 3, 302-309.	0.6	13
60	Short-Term Acetylsalicylic Acid (Aspirin) Use for Pain, Fever, or Colds â€”Gastrointestinal Adverse Effects. Drugs in R and D, 2011, 11, 277-288.	1.1	38
61	BMJ tackles FDA's mote in eye while ignoring own beam. BMJ: British Medical Journal, 2011, 343, d5614-d5614.	2.4	0
62	Francis Galton and Regression to the Mean. Significance, 2011, 8, 124-126.	0.3	32
63	Review of Fleiss, statistical methods for rates and proportions. Research Synthesis Methods, 2011, 2, 221-222.	4.2	35
64	Creating a suite of macros for meta-analysis in SAS®: A case study in collaboration. Statistics and Probability Letters, 2011, 81, 842-851.	0.4	17
65	Investigating variability in patient response to treatment â€” a case study from a replicate cross-over study. Statistical Methods in Medical Research, 2011, 20, 657-666.	0.7	46
66	Hans van Houwelingen and the Art of Summing up. Biometrical Journal, 2010, 52, 85-94.	0.6	49
67	Comparisons of minimization and Atkinson's algorithm. Statistics in Medicine, 2010, 29, 721-730.	0.8	26
68	Planning and analysis of cross-over trials in infertility. Statistics in Medicine, 2010, 29, 3203-3210.	0.8	20
69	Significant errors. Lancet, The, 2010, 376, 1390-1391.	6.3	1
70	Crossover Design. , 2010, , 380-385.		2
71	<i>P</i>-Values. , 2010, , 940-948.		0
72	Adverse Gastrointestinal Effects of Brief Use of Full Strength, OTC Aspirin in Randomized Clinical Trials: A Meta-Analysis. American Journal of Gastroenterology, 2010, 105, S393.	0.2	0

#	ARTICLE	IF	CITATIONS
73	Placebo Misconceptions. American Journal of Bioethics, 2009, 9, 53-54.	0.5	8
74	Overstating the evidence â€“ double counting in meta-analysis and related problems. BMC Medical Research Methodology, 2009, 9, 10.	1.4	134
75	Measurement in clinical trials: A neglected issue for statisticians?. Statistics in Medicine, 2009, 28, 3189-3209.	0.8	115
76	Authors' Rejoinder to Commentaries on â€“Measurement in clinical trials: A neglected issue for statisticians?â€™. Statistics in Medicine, 2009, 28, 3223-3225.	0.8	0
77	Commentary on â€“Designs for doseâ€“escalation trials with quantitative responsesâ€™. Statistics in Medicine, 2009, 28, 3754-3758.	0.8	7
78	Lessons from TGN1412 and TARGET: implications for observational studies and metaâ€“analysis. Pharmaceutical Statistics, 2008, 7, 294-301.	0.7	17
79	Statisticians and evidence â€“ mote and beam. Pharmaceutical Statistics, 2008, 7, 155-157.	0.7	0
80	A century of <i>T</i>-tests. Significance, 2008, 5, 37-39.	0.3	11
81	The t-test tool. Significance, 2008, 5, 40-41.	0.3	4
82	Editorial/Letters. Significance, 2008, 5, 92-93.	0.3	1
83	A 4-Year Trial of Tiotropium in Chronic Obstructive Pulmonary Disease. New England Journal of Medicine, 2008, 359, 1543-1554.	13.9	1,969
84	Bronchodilation of formoterol administered with budesonide: Device and formulation effects. Contemporary Clinical Trials, 2008, 29, 114-124.	0.8	13
85	A Note Concerning a Selection â€œParadoxâ€“of Dawid's. American Statistician, 2008, 62, 206-210.	0.9	40
86	Transposed Conditionals, Shrinkage, and Direct and Indirect Unbiasedness. Epidemiology, 2008, 19, 652-654.	1.2	12
87	Comment on article by Gelman. Bayesian Analysis, 2008, 3, .	1.6	26
88	Meta-Analysis Combining 2 Previously Reported Trials on Respiratory Distress Syndrome in Neonates. Pediatrics, 2007, 120, 1224-1225.	1.0	1
89	Power and sample size when multiple endpoints are considered. Pharmaceutical Statistics, 2007, 6, 161-170.	0.7	90
90	Trying to be precise about vagueness. Statistics in Medicine, 2007, 26, 1417-1430.	0.8	99

#	ARTICLE	IF	CITATIONS
91	Stratification for the propensity score compared with linear regression techniques to assess the effect of treatment or exposure. <i>Statistics in Medicine</i> , 2007, 26, 5529-5544.	0.8	69
92	Statistical issues in first-in-man studies. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2007, 170, 517-579.	0.6	40
93	Safety first?. <i>Significance</i> , 2007, 4, 79-80.	0.3	2
94	Drawbacks to Noninteger Scoring for Ordered Categorical Data. <i>Biometrics</i> , 2007, 63, 296-298.	0.8	11
95	Probabilistic index: an intuitive non-parametric approach to measuring the size of the treatment effects by L. Acion, J. J. Peterson, S. Temple and S. Arndt, <i>Statistics in Medicine</i> 2006;25(4):591-602. <i>Statistics in Medicine</i> , 2006, 25, 3944-3946.	0.8	14
96	Change from baseline and analysis of covariance revisited. <i>Statistics in Medicine</i> , 2006, 25, 4334-4344.	0.8	267
97	Cross-over trials in <i>Statistics in Medicine</i> : the first 25 years. <i>Statistics in Medicine</i> , 2006, 25, 3430-3442.	0.8	81
98	Sharp tongues and bitter pills. <i>Significance</i> , 2006, 3, 123-125.	0.3	2
99	Epigenetics or ephemeral genetics?. <i>European Journal of Human Genetics</i> , 2006, 14, 1149-1149.	1.4	10
100	An Early "Atkins' Diet" RA Fisher Analyses a Medical "Experiment". <i>Biometrical Journal</i> , 2006, 48, 193-204.	0.6	3
101	Early piribedil monotherapy of Parkinson's disease: A planned seven-month report of the REGAIN study. <i>Movement Disorders</i> , 2006, 21, 2110-2115.	2.2	61
102	JAMA's policy does not go far enough. <i>BMJ: British Medical Journal</i> , 2006, 332, 305.2.	2.4	2
103	Analysis: Repeated Measures in Clinical Trials: Simple Strategies for Analysis Using Summary Measures. , 2005, , 379-395.		0
104	"Equivalence is Different" " Some Comments on Therapeutic Equivalence. <i>Biometrical Journal</i> , 2005, 47, 104-107.	0.6	11
105	An unreasonable prejudice against modelling?. <i>Pharmaceutical Statistics</i> , 2005, 4, 87-89.	0.7	14
106	Misunderstandings regarding clinical cross-over trials. <i>Statistics in Medicine</i> , 2005, 24, 3675-3678.	0.8	6
107	Bitter Pills and Puffed Trials. <i>PLoS Medicine</i> , 2005, 2, e219.	3.9	2
108	When is a drug not a drug?. <i>Significance</i> , 2004, 1, 159-161.	0.3	1

#	ARTICLE	IF	CITATIONS
109	Controversies concerning randomization and additivity in clinical trials. <i>Statistics in Medicine</i> , 2004, 23, 3729-3753.	0.8	109
110	The analysis of the AB/BA cross-over trial in the medical literature. <i>Pharmaceutical Statistics</i> , 2004, 3, 123-131.	0.7	6
111	Carry-over in cross-over trials in bioequivalence: theoretical concerns and empirical evidence. <i>Pharmaceutical Statistics</i> , 2004, 3, 133-142.	0.7	37
112	Individual response to treatment: is it a valid assumption?. <i>BMJ: British Medical Journal</i> , 2004, 329, 966-968.	2.4	130
113	Turning a blind eye: Authors have blinkered view of blinding. <i>BMJ: British Medical Journal</i> , 2004, 328, 1135.3-1136.	2.4	18
114	JOHN NELDER: FROM GENERAL BALANCE TO GENERALISED MODELS (BOTH LINEAR AND HIERARCHICAL). , 2004, , 1-11.		3
115	Lost opportunities for statistics. <i>Pharmaceutical Statistics</i> , 2003, 2, 3-4.	0.7	3
116	Examples of option values in drug development. <i>Pharmaceutical Statistics</i> , 2003, 2, 113-125.	0.7	18
117	Disappointing dichotomies. <i>Pharmaceutical Statistics</i> , 2003, 2, 239-240.	0.7	82
118	A note on non-parametric ANCOVA for covariate adjustment in randomized clinical trials. <i>Statistics in Medicine</i> , 2003, 22, 3583-3596.	0.8	31
119	Editorial: Pharmaceuticals, patents and competition-some statistical issues. <i>Journal of the Royal Statistical Society Series A: Statistics in Society</i> , 2003, 166, 271-274.	0.6	4
120	Foreword: A blue plaque for Fisher. <i>Journal of the Royal Statistical Society: Series D (the Statistician)</i> , 2003, 52, 297-298.	0.2	1
121	A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations. <i>Clinical Therapeutics</i> , 2003, 25, 1295-1320.	1.1	163
122	A Conversation with John Nelder. <i>Statistical Science</i> , 2003, 18, 118.	1.6	9
123	Competing interests. <i>BMJ: British Medical Journal</i> , 2003, 326, 883-883.	2.4	2
124	Ethics of clinical trials from bayesian perspective: Society's role is important. <i>BMJ: British Medical Journal</i> , 2003, 326, 1456-b-1457.	2.4	3
125	Ethical considerations concerning treatment allocation in drug development trials. <i>Statistical Methods in Medical Research</i> , 2002, 11, 403-411.	0.7	34
126	The Unpleasant Placebo?. <i>Chance</i> , 2002, 15, 27-29.	0.1	0

#	ARTICLE	IF	CITATIONS
127	A comment on replication,p-values and evidence S.N.Goodman,Statistics in Medicine 1992;11:875-879. Statistics in Medicine, 2002, 21, 2437-2444.	0.8	70
128	Authorship of drug industry trials. Pharmaceutical Statistics, 2002, 1, 5-7.	0.7	7
129	Power is indeed irrelevant in interpreting completed studies. BMJ, The, 2002, 325, 1304.	3.0	10
130	Screening for breast cancer with mammography. Lancet, The, 2001, 358, 2165.	6.3	17
131	Cross-over trials in drug development: theory and practice. Journal of Statistical Planning and Inference, 2001, 96, 29-40.	0.4	9
132	Surveillance of antimicrobial resistance " what, how and whither?. Clinical Microbiology and Infection, 2001, 7, 316-325.	2.8	117
133	Statistical issues in bioequivalence. Statistics in Medicine, 2001, 20, 2785-2799.	0.8	53
134	Two cheers for P-values?. Journal of Epidemiology and Biostatistics, 2001, 6, 193-204.	0.4	88
135	Repeated measures in clinical trials: simple strategies for analysis using summary measures. , 2000, 19, 861-877.		102
136	Consensus and Controversy in Pharmaceutical Statistics. Journal of the Royal Statistical Society: Series D (the Statistician), 2000, 49, 135-176.	0.2	71
137	Letter to the editor. Contemporary Clinical Trials, 2000, 21, 589-592.	2.0	7
138	Screening mammography re-evaluated. Lancet, The, 2000, 355, 750.	6.3	10
139	Letters to the editor. Annals of Allergy, Asthma and Immunology, 2000, 84, 639.	0.5	8
140	Clinical cross-over trials in phase I. Statistical Methods in Medical Research, 1999, 8, 263-278.	0.7	16
141	A Comment on Optimal Allocations for Bioequivalence Studies. Biometrics, 1999, 55, 1314-1315.	0.8	4
142	Investigating underlying risk as a source of heterogeneity in meta-analysis by S. G. Thompson, T. C. Smith and S. J. Sharp,Statistics in Medicine,16, 2741-2758 (1997). , 1999, 18, 110-115.		29
143	Preface. , 1999, 18, 1739-1739.		1
144	Investigating underlying risk as a source of heterogeneity in meta-analysis by S. G. Thompson, T. C. Smith and S. J. Sharp, Statistics in Medicine, 16, 2741-2758 (1997). , 1999, 18, 110.		1

#	ARTICLE	IF	CITATIONS
145	Mathematics Governess or Handmaiden?. Journal of the Royal Statistical Society: Series D (the Tj ETQq1 1 0.784314.rgBT /Oyerlock 10	0.2	0
146	Some controversies in planning and analysing multi-centre trials. , 1998, 17, 1753-1765.		138
147	Robust and realistic approaches to carry-over. , 1998, 17, 2849-2864.		30
148	In the blood: proposed new requirements for registering generic drugs. Lancet, The, 1998, 352, 85-86.	6.3	27
149	Estimating treatment effects in clinical crossover trials. Journal of Biopharmaceutical Statistics, 1998, 8, 191-233.	0.4	27
150	Further Statistical Issues in Project Prioritization in the Pharmaceutical Industry. Drug Information Journal, 1998, 32, 253-259.	0.5	13
151	Some controversies in planning and analysing multi-centre trials. , 1998, 17, 1753.		1
152	Some controversies in planning and analysing multi-centre trials. , 1998, 17, 1753.		1
153	Robust and realistic approaches to carry-over. Statistics in Medicine, 1998, 17, 2849-2864.	0.8	1
154	LETTER TO THE EDITOR: Testing for Individual and Population Equivalence Based on the Proportion of Similar Responses, by D. M. Rom and E. Hwang,Statistics in Medicine,15, 1489-1505 (1996). Statistics in Medicine, 1997, 16, 1303-1305.	0.8	22
155	LETTER TO THE EDITOR: The case for cross-over trials in phase III by B. J. Jones and J. Lewis,Statistics in Medicine,14, 1025-1038 (1995). , 1997, 16, 2021-2022.		12
156	A Comment on Interim Analyses in Crossover Trials. Biometrics, 1996, 52, 1515.	0.8	2
157	LETTER TO THE EDITOR INCLUDING AUTHOR'S REPLY: A PERSONAL VIEW OF SOME CONTROVERSIES IN ALLOCATING TREATMENT TO PATIENTS IN CLINICAL TRIALS by Stephen Senn,Statistics in Medicine,14, 2661-2674 (1995). , 1996, 15, 113-116.		0
158	SOME STATISTICAL ISSUES IN PROJECT PRIORITIZATION IN THE PHARMACEUTICAL INDUSTRY. , 1996, 15, 2689-2702.		33
159	Baseline balance and conditional size: a reply to overall Et al. Journal of Biopharmaceutical Statistics, 1996, 6, 201-210.	0.4	2
160	In defence of analysis of covariance: A reply to Chambless and Roebach. Statistics in Medicine, 1995, 14, 2283-2285.	0.8	17
161	A personal view of some controversies in allocating treatment to patients in clinical trials. Statistics in Medicine, 1995, 14, 2661-2674.	0.8	46
162	Caution in interpretation needed. BMJ: British Medical Journal, 1995, 310, 667-667.	2.4	13

#	ARTICLE	IF	CITATIONS
163	The AB/BA crossover: past, present and future?. <i>Statistical Methods in Medical Research</i> , 1994, 3, 303-324.	0.7	57
164	Repeated measures in clinical trials: Analysis using mean summary statistics and its implications for design. <i>Statistics in Medicine</i> , 1994, 13, 197-198.	0.8	176
165	Fisher's game with the devil. <i>Statistics in Medicine</i> , 1994, 13, 217-230.	0.8	71
166	Importance of trends in the interpretation of an overall odds ratio in the meta-analysis of clinical trials. <i>Statistics in Medicine</i> , 1994, 13, 293-296.	0.8	61
167	The first t-test. <i>Statistics in Medicine</i> , 1994, 13, 785-803.	0.8	42
168	Regression to the mean and crossover trials revisited. <i>Statistics in Medicine</i> , 1994, 13, 1181-1186.	0.8	2
169	Testing for baseline balance in clinical trials. <i>Statistics in Medicine</i> , 1994, 13, 1715-1726.	0.8	393
170	Methods for assessing difference between groups in change when initial measurement is subject to intra-individual variation. <i>Statistics in Medicine</i> , 1994, 13, 2280-2285.	0.8	24
171	A Comment on CHI, E. M., 1992: Analysis of cross-over trials when within-subject errors follow an AR(1) process. <i>Biom. J.</i> 34, 359-365. <i>Biometrical Journal</i> , 1994, 36, 125-128.	0.6	1
172	Regression toward the mean in 2 \times 2 crossover designs with baseline measurements. <i>Statistics in Medicine</i> , 1993, 12, 1086-1087.	0.8	1
173	A random effects model for ordinal responses from a crossover trial. by F. Ezzet and J. Whitehead, <i>Statistics in Medicine</i> , 1993, 12, 2147-2151.	0.8	13
174	Inherent difficulties with active control equivalence studies. <i>Statistics in Medicine</i> , 1993, 12, 2367-2375.	0.8	41
175	Suspended judgment n-of-1 trials. <i>Contemporary Clinical Trials</i> , 1993, 14, 1-5.	2.0	21
176	Baseline distribution and conditional size. <i>Journal of Biopharmaceutical Statistics</i> , 1993, 3, 265-270.	0.4	7
177	Is the "simple carry-over" model useful?. <i>Statistics in Medicine</i> , 1992, 11, 715-726.	0.8	71
178	Problems with the two stage analysis of crossover trials [letter; comment]. <i>British Journal of Clinical Pharmacology</i> , 1991, 32, 133-711.	1.1	22
179	Crossover trials, degrees of freedom, the carryover problem and its dual. <i>Statistics in Medicine</i> , 1991, 10, 1361-1374.	0.8	34
180	Falsificationism and clinical trials. <i>Statistics in Medicine</i> , 1991, 10, 1679-1692.	0.8	77

#	ARTICLE	IF	CITATIONS
181	Covariance analysis in generalized linear measurement error models. <i>Statistics in Medicine</i> , 1990, 9, 583-586.	0.8	7
182	The graphical representation of clinical trials with particular reference to measurements over time. <i>Statistics in Medicine</i> , 1990, 9, 1287-1302.	0.8	36
183	Regression: A New Mode for an Old Meaning?. <i>American Statistician</i> , 1990, 44, 181.	0.9	11
184	Covariate imbalance and random allocation in clinical trials. <i>Statistics in Medicine</i> , 1989, 8, 467-475.	0.8	240
185	The use of baselines in clinical trials of bronchodilators. <i>Statistics in Medicine</i> , 1989, 8, 1339-1350.	0.8	51
186	Combining Outcome Measures: Statistical Power Is Irrelevant. <i>Biometrics</i> , 1989, 45, 1027.	0.8	14
187	Maximum likelihood estimation of treatment effects for samples subject to regression to the mean. <i>Communications in Statistics - Theory and Methods</i> , 1989, 18, 3389-3406.	0.6	19
188	Cross-over trials, carry-over effects and the art of self-delusion. <i>Statistics in Medicine</i> , 1988, 7, 1099-1101.	0.8	54
189	A Note Concerning the Analysis of an Epidemic of Q Fever. <i>International Journal of Epidemiology</i> , 1988, 17, 891-893.	0.9	6
190	Sober view of AIDS. <i>Nature</i> , 1987, 328, 10-10.	13.7	1
191	Estimating Treatment Effects in Clinical Trials Subject to Regression to the Mean. <i>Biometrics</i> , 1985, 41, 555.	0.8	42
192	Intention to Treat, Missing Data and Related Matters. , 0, , 165-181.		0
193	One-Sided and Two-Sided Tests and other Issues to Do with Significance and P-Values. , 0, , 183-193.		2
194	Design and Interpretation of Clinical Trials as Seen by a Statistician. , 0, , 27-42.		1
195	Does evidence support the high expectations placed in precision medicine? A bibliographic review. <i>F1000Research</i> , 0, 7, 30.	0.8	7
196	Does evidence support the high expectations placed in precision medicine? A bibliographic review. <i>F1000Research</i> , 0, 7, 30.	0.8	8
197	Misunderstanding publication bias: editors are not blameless after all. <i>F1000Research</i> , 0, , .	0.8	1
198	Modelling in Radioactive Waste Disposal. , 0, , 173-185.		0

#	ARTICLE	IF	CITATIONS
199	The Work of the Pharmaceutical Statistician. , 0, , 55-66.		1
200	Multiplicity. , 0, , 149-164.		0
201	Determining the Sample Size. , 0, , 195-212.		6
202	Multicentre Trials. , 0, , 213-233.		0
203	Active Control Equivalence Studies. , 0, , 235-250.		0
204	Cross-over Trials. , 0, , 273-285.		7
205	n-of-1 Trials. , 0, , 287-294.		0
206	Sequential Trials. , 0, , 295-315.		0
207	A Brief and Superficial History of Statistics for Drug Developers. , 0, , 9-25.		0
208	Dose-Finding. , 0, , 317-336.		0
209	Concerning Pharmacokinetics and Pharmacodynamics. , 0, , 337-360.		0
210	Bioequivalence Studies. , 0, , 361-381.		0
211	Safety Data, Harms, Drug Monitoring and Pharmaco-Epidemiology. , 0, , 383-404.		0
212	Pharmaco-Economics and Portfolio Management. , 0, , 405-431.		0
213	Concerning Pharmacogenetics, Pharmacogenomics and Related Matters. , 0, , 433-452.		0
214	Probability, Bayes,P-Values, Tests of Hypotheses and Confidence Intervals. , 0, , 43-53.		0
215	Allocating Treatments to Patients in Clinical Trials. , 0, , 67-93.		0
216	The Measurement of Treatment Effects. , 0, , 113-131.		0

#	ARTICLE	IF	CITATIONS
217	Demographic Subgroups: Representation and Analysis. , 0, , 133-148.		0
218	Statistics in Practice. , 0, , 499-500.		0